Bimekizumab Application Scope

Bimekizumab, marketed under the bimekizumab brand name Bimzelx®, is a humanized monoclonal antibody that inhibits interleukin (IL)-17A and IL-17F, cytokines involved in inflammatory processes.

It is indicated for the treatment of several inflammatory conditions.

Bimzelx® Injection is approved for use in adults with the following conditions:

Moderate to severe plaque psoriasis: For patients who are candidates for systemic therapy or phototherapy.
Active psoriatic arthritis: Alone or in combination with methotrexate, for patients who have had an inadequate response or intolerance to prior disease-modifying antirheumatic drug (DMARD) therapy.
Active ankylosing spondylitis: For patients who have responded inadequately to conventional therapy.
Active non-radiographic axial spondyloarthritis: With objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), in patients who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Moderate to severe hidradenitis suppurativa: For patients who have not responded adequately to conventional therapy.

bimekizumab

Bimekizumab Bimzelx Package Insert

Ingredients: Each pre-filled syringe or autoinjector contains 160 mg of bimekizumab in 1 mL solution (160 mg/mL).
Properties: Bimekizumab is a recombinant humanized IgG1 monoclonal antibody that selectively binds to IL-17A and IL-17F, inhibiting their interaction with receptors and thereby modulating inflammatory responses.
Specification: Solution for injection; clear to slightly opalescent, and pale brownish-yellow.
Packaging Specification: Available in pre-filled syringes or autoinjectors, each containing 160 mg of bimekizumab.
Storage: Store in a refrigerator (2°C–8°C). Do not freeze. Keep the pre-filled syringe or autoinjector in the original carton to protect from light.
Expiry Date: Refer to the expiry date printed on the packaging.
Executive Standard: Refer to the prescribing information or local regulatory guidelines for detailed standards.
Approval Number: Varies by country; consult local regulatory authorities for specific approval numbers.
Date of Revision: Refer to the prescribing information for the most recent revision date.
Manufacturer: UCB Pharma.

Guidelines For The Use Of Bimekizumab

Dosage and Administration:
- Plaque Psoriasis: Administer 320 mg (two 160 mg injections) at Weeks 0, 4, 8, 12, and 16, followed by 320 mg every 8 weeks. For patients weighing ≥120 kg, a dose of 320 mg every 4 weeks after Week 16 may be considered.
- Psoriatic Arthritis and Ankylosing Spondylitis: Administer 160 mg every 4 weeks.
- Non-Radiographic Axial Spondyloarthritis: Administer 160 mg every 4 weeks.
- Hidradenitis Suppurativa: Administer 320 mg every 2 weeks for the initial 16 weeks, followed by 320 mg every 4 weeks.
- Administration: Subcutaneous injection; may be administered by a healthcare professional or self-injected after proper training.
Bimzelx Side Effects
- Upper respiratory tract infections, oral candidiasis, injection site reactions, and potential suicidal ideation and behavior.
Contraindications:
- Known hypersensitivity to bimekizumab or any of its excipients.
Precautions:
- Evaluate patients for tuberculosis infection prior to initiation.
- Monitor liver enzymes, alkaline phosphatase, and bilirubin levels before starting treatment.
- Advise patients and caregivers to monitor for signs of depression or suicidal thoughts.

Bimekizumab Bimzelx Interactions

Drug Interactions:
- No specific drug-drug interaction studies have been conducted. Caution is advised when co-administering live vaccines or immunosuppressive therapies.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.